

New opportunities in Natural Product Drug Discovery

Kappei Tsukahara, Ph.D. Eisai Co., Ltd. April 9th, 2019




Overview of the drug discovery process Eisai from natural products ~ a long journey ~ **Material access** NP database **Bioactive** Clinical Marine-organism **Micro-organism Natural Samples** natural product trial (tens of thousands samples) Optimization Screening **Purification** Scale up production Drug candidate

Hit Extract

Find a hit extract (


Natural products drug discovery in Eisai





Why Halichondrin B?






Why NOT Halichondrin B as a drug?

• Extremely limited material supply from natural sources required for discovery research, clinical development and commercial production

Chemical beauty of Eribulin enabled by powerful synthetic chemistry





Pladienolide B as a unique "Drug Lead"






Novel chemical structure

- Unique mechanism of action
- Highly potent in vitro & in vivo


Complete remission was observed in vivo xenograft model





From Pladienolide B to E7107 with microbial and chemical conversion technologies







New technology reveals precise binding mode of E7107 to the target protein



Cryo-EM technology enabled protein structure analysis of huge and dynamic target complex like spliceosome



New opportunity for NP drug discovery Natural product meets new demands and technologies



Targeting protein complex as well as **protein-protein interaction**


Assay technology Phenotypic screening system such as **iPS cell-derived human disease models** New era of "NP" Drug Discovery

Synthetic biology

Natural products are "Genetic products" that can be modified by genetic manipulation



Discover new NPs through APAC NPDD Consortium Esai Constructing unique and sustainable collaboration mechanism in Asia



N²PC: Technology Research Association for Next generation natural products chemistry IMC: Institute of Microbial Chemistry